BioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of Chile

BioCryst Pharmaceuticals, Inc. (BCRX) announced Monday that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.

Related Keywords

Pleasant Grove ,Florida ,United States ,South Korea ,South Korean ,Josh Damaro ,Ron Desantis ,Nature Energy ,Kia Corp ,Drug Administration ,Disney ,Hyundai Motor ,Utah Based Nature ,Chewable Colostrum ,Childrens Chewable Colostrum Berry ,Orange Creamsicle ,Biocryst Pharmaceuticals ,Biocryst ,Biocryst Pharma ,Pcrx ,Pint Pharma ,Berotralstat ,Orladeyo ,